(Q33232599)

24 July 2017

1 reference

title

Pharmacological advances in the treatment of invasive candidiasis (English)

1 reference

24 July 2017

1 reference

1 reference

Daniel H Deck

1

1 reference

24 July 2017

B Joseph Guglielmo

series ordinal

2

1 reference

24 July 2017

publication date

1 February 2006

1 reference

Expert Review of Anti-infective Therapy

24 July 2017

published in

1 reference

24 July 2017

volume

4

1 reference

24 July 2017

issue

1

1 reference

24 July 2017

page(s)

137-149

1 reference

National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. SCOPE Participant Group. Surveillance and Control of Pathog

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

The epidemiology of candidemia in two United States cities: results of a population-based active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Amphotericin B: time for a new "gold standard".

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Antifungal Agents Used in Systemic Mycoses Activity and Therapeutic Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Clinical pharmacokinetics of systemic antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Nephrotoxicity of amphotericin B, with emphasis on changes in tubular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Comparison of caspofungin and amphotericin B for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Sodium protects against nephrotoxicity in patients receiving amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Effect of salt supplementation on amphotericin B nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

The hepatotoxicity of antifungal medications in bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Amphotericin B colloidal dispersion for treatment of candidemia in immunocompromised patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Voriconazole: a new triazole antifungal agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Epidemiology of Candida species infections in critically ill non-immunosuppressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

The effect of empiric and prophylactic treatment with fluconazole on yeast isolates in a surgical trauma intensive care unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Antifungal resistance in pathogenic fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Comparison of the susceptibilities of Candida spp. to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

High-dose therapy with fluconazole > or = 800 mg day-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Voriconazole salvage treatment of invasive candidiasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Mortality and costs of acute renal failure associated with amphotericin B therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

Revisiting the Source of Candidemia: Skin or Gut?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.4.1.137

21 January 2018

Identifiers

DOI

10.1586/14787210.4.1.137

1 reference

24 July 2017

1 reference